1. Home
  2. WTBA vs CBIO Comparison

WTBA vs CBIO Comparison

Compare WTBA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Bancorporation

WTBA

West Bancorporation

HOLD

Current Price

$23.80

Market Cap

375.9M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$14.99

Market Cap

340.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTBA
CBIO
Founded
1893
2003
Country
United States
United States
Employees
N/A
44
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
375.9M
340.4M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
WTBA
CBIO
Price
$23.80
$14.99
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$24.00
$26.67
AVG Volume (30 Days)
28.1K
160.9K
Earning Date
04-23-2026
02-26-2026
Dividend Yield
4.19%
N/A
EPS Growth
35.21
N/A
EPS
1.92
N/A
Revenue
N/A
N/A
Revenue This Year
$23.69
N/A
Revenue Next Year
$9.18
$355.04
P/E Ratio
$12.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.33
$8.72
52 Week High
$26.60
$17.39

Technical Indicators

Market Signals
Indicator
WTBA
CBIO
Relative Strength Index (RSI) 47.60 70.33
Support Level $23.57 $11.88
Resistance Level $24.16 $15.66
Average True Range (ATR) 0.72 1.13
MACD 0.05 0.29
Stochastic Oscillator 67.10 95.08

Price Performance

Historical Comparison
WTBA
CBIO

About WTBA West Bancorporation

West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: